Related Experiment Video

Updated: Jun 19, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Aurora-A kinase: a novel target both for cellular immunotherapy and molecular target therapy against human leukemia

Toshiki Ochi1, Hiroshi Fujiwara, Masaki Yasukawa

  • 1Ehime University Graduate School of Medicine, Department of Bioregulatory Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan.

Expert Opinion on Therapeutic Targets
|October 14, 2009
PubMed
Abstract

Insights

Aurora-A kinase shows promise as a target for both cellular immunotherapy and small-molecule inhibitor therapy against cancer. This kinase is crucial for cell division and implicated in tumorigenesis, making it an attractive therapeutic target.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Cellular immunotherapy is an emerging cancer treatment requiring specific target antigens.
  • Aurora-A kinase (Aurora-A) is implicated in cell division and tumorigenesis.
  • Aurora-A is a potential target for immunotherapy and small-molecule inhibitors.

Purpose of the Study:

  • This review covers Aurora-A kinase as a target in cancer therapy.
  • Focuses on immunotherapy and small-molecule inhibitor approaches.
  • Highlights Aurora-A's potential in comprehensive cancer treatment.

Main Methods:

  • Review of existing literature on Aurora-A kinase.
  • Analysis of its role in cancer cell division.
  • Examination of preclinical and clinical data for inhibitors and immunotherapy.

Main Results:

  • Aurora-A kinase is a well-recognized target in human leukemia.
  • Small-molecule inhibitors of Aurora-A show promising Phase I clinical trial results.
  • Aurora-A is validated as a target for cellular immunotherapy.

Conclusions:

  • Aurora-A kinase is a highly attractive target for developing novel cancer therapies.
  • It serves as a target for both small-molecule inhibitors and immunotherapy.
  • Comprehensive cancer treatment strategies can leverage Aurora-A targeting.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...